Vaxcyte Inc

Trading Arrangements

The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers or directors for the three months ended March 31, 2024, each of which was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (“10b5-1 Plan”), were as follows:

Halley Gilbert, our Board and Audit Committee member, adopted a 10b5-1 Plan on March 1, 2024. Ms. Gilbert’s 10b5-1 Plan provides for the potential exercise and sale of up to 51,950 shares of our common stock, and expires on May 31, 2025, or upon the earlier completion of all authorized transactions thereunder.

Jim Wassil, our Chief Operating Officer, adopted a 10b5-1 Plan on March 1, 2024. Mr. Wassil’s 10b5-1 Plan provides for the potential exercise and sale of up to 108,000 shares of our common stock, and expires on September 1, 2025, or upon the earlier completion of all authorized transactions thereunder.

During the three months ended March 31, 2024, none of the Company’s other directors or Section 16 officers adopted, modified or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).